Detailed price information for Celldex Therapeutics (CLDX-Q) from The Globe and Mail including charting and trades.
Melanie Stein, ND Clinical improvement in treatment-refractory MCAS with normal conventional biomarkers and profound oral ...
A case report demonstrating sequential neurorepair, lipid repletion, microbiome stabilization, and mitochondrial support in ...
Doctors are divided over treatment for a rare disorder, but some living with it say the official advice is misleading.
Blueprint Medicines, a Sanofi company, today announced AYVAKIT(R) (avapritinib) data showing clinically meaningful outcomes and a w ...
Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients ...
Patients with chronic spontaneous urticaria had positive outcomes weeks after barzolvolimab, according to data presented at ...
Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six ...
Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...
Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results